Preferredfrequencyof GnRHagonistsThis drug class iscontraindicatedcombined withtrastuzumab-avoid for 7 monthsafter lasttrastuzumab dosePatients withHER2+ diseasecontinuetargetedtherapy for thisdurationThis CDK 4/6inhibitor is the onlyone in its drugclass also used inearly stage breastcancer1%The onlysteroidalaromataseinhibitor in itsdrug classBased onOncotype DX,a score of 35will receivethis treatmentPreferredregimen forHR+ diseasefor frail/elderlypatientsThis agent iswell studied fortamoxifeninduced hotflashes inbreast cancerThis prodrug isgiven in TNBC forpatients who do notachieve pathologiccomplete responsebased on CREATE-X trialThis treatmentmodality isalwayscombined withlumpectomysurgeryUsed asneoadjuvant andadjuvant therapyin high risk TNBCbased on theKEYNOTE 522trialI can give thisagent in highrisk BRCA1/2 mutationfor 1 yearThe ATLAS,AttOM, MA.17Rtrials evaluatedthis durationbenefit ofendocrine therapyThis subtype ofbreast cancerhas the lowestrelative 5-yearsurvival rate This should bemonitoredroutinely every3-4 monthswhile receivingtrastuzumab Patients who donot achieve pCRin HER2+disease and haveresidual diseaseget this therapyThis drugclass are thebackbone ofHR+ diseaseDuration of timepatients willtakeabemaciclib inearly stagediseaseBased onTAILORx, <50years receivechemoendocrinetherapy if theyhave thisOncotypeDx score This agent is notused inpremenopausalwomen as endocrinetherapy unless theyalso receive ovariansuppression This agentshould beinitiated withneratinib for thefirst 8 weeksThis agent cancauseendometrialcancer, but hasbone densityprotective effectThis agent canbe added toLN+ HER2+disease givenwithtrastuzumabPreferredfrequencyof GnRHagonistsThis drug class iscontraindicatedcombined withtrastuzumab-avoid for 7 monthsafter lasttrastuzumab dosePatients withHER2+ diseasecontinuetargetedtherapy for thisdurationThis CDK 4/6inhibitor is the onlyone in its drugclass also used inearly stage breastcancer1%The onlysteroidalaromataseinhibitor in itsdrug classBased onOncotype DX,a score of 35will receivethis treatmentPreferredregimen forHR+ diseasefor frail/elderlypatientsThis agent iswell studied fortamoxifeninduced hotflashes inbreast cancerThis prodrug isgiven in TNBC forpatients who do notachieve pathologiccomplete responsebased on CREATE-X trialThis treatmentmodality isalwayscombined withlumpectomysurgeryUsed asneoadjuvant andadjuvant therapyin high risk TNBCbased on theKEYNOTE 522trialI can give thisagent in highrisk BRCA1/2 mutationfor 1 yearThe ATLAS,AttOM, MA.17Rtrials evaluatedthis durationbenefit ofendocrine therapyThis subtype ofbreast cancerhas the lowestrelative 5-yearsurvival rate This should bemonitoredroutinely every3-4 monthswhile receivingtrastuzumab Patients who donot achieve pCRin HER2+disease and haveresidual diseaseget this therapyThis drugclass are thebackbone ofHR+ diseaseDuration of timepatients willtakeabemaciclib inearly stagediseaseBased onTAILORx, <50years receivechemoendocrinetherapy if theyhave thisOncotypeDx score This agent is notused inpremenopausalwomen as endocrinetherapy unless theyalso receive ovariansuppression This agentshould beinitiated withneratinib for thefirst 8 weeksThis agent cancauseendometrialcancer, but hasbone densityprotective effectThis agent canbe added toLN+ HER2+disease givenwithtrastuzumab

BC questions - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
  1. Preferred frequency of GnRH agonists
  2. This drug class is contraindicated combined with trastuzumab- avoid for 7 months after last trastuzumab dose
  3. Patients with HER2+ disease continue targeted therapy for this duration
  4. This CDK 4/6 inhibitor is the only one in its drug class also used in early stage breast cancer
  5. 1%
  6. The only steroidal aromatase inhibitor in its drug class
  7. Based on Oncotype DX, a score of 35 will receive this treatment
  8. Preferred regimen for HR+ disease for frail/elderly patients
  9. This agent is well studied for tamoxifen induced hot flashes in breast cancer
  10. This prodrug is given in TNBC for patients who do not achieve pathologic complete response based on CREATE-X trial
  11. This treatment modality is always combined with lumpectomy surgery
  12. Used as neoadjuvant and adjuvant therapy in high risk TNBC based on the KEYNOTE 522 trial
  13. I can give this agent in high risk BRCA 1/2 mutation for 1 year
  14. The ATLAS, AttOM, MA.17R trials evaluated this duration benefit of endocrine therapy
  15. This subtype of breast cancer has the lowest relative 5-year survival rate
  16. This should be monitored routinely every 3-4 months while receiving trastuzumab
  17. Patients who do not achieve pCR in HER2+ disease and have residual disease get this therapy
  18. This drug class are the backbone of HR+ disease
  19. Duration of time patients will take abemaciclib in early stage disease
  20. Based on TAILORx, <50 years receive chemoendocrine therapy if they have this OncotypeDx score
  21. This agent is not used in premenopausal women as endocrine therapy unless they also receive ovarian suppression
  22. This agent should be initiated with neratinib for the first 8 weeks
  23. This agent can cause endometrial cancer, but has bone density protective effect
  24. This agent can be added to LN+ HER2+ disease given with trastuzumab